)
Nikita Vashisht is a business journalist tracking equity markets for Business Standard. She writes stories based on fundamental analysis of stocks of banking, aviation, FMCG, infrastructure, real estate, and new-age companies. Occasionally, she also writes on investment strategies for mutual fund investors. Nikita holds a degree in journalism, and business management, and is a certified fundamental and technical analyst for stocks and commodities.
Nikita Vashisht is a business journalist tracking equity markets for Business Standard. She writes stories based on fundamental analysis of stocks of banking, aviation, FMCG, infrastructure, real estate, and new-age companies. Occasionally, she also writes on investment strategies for mutual fund investors. Nikita holds a degree in journalism, and business management, and is a certified fundamental and technical analyst for stocks and commodities.
Indian IT stocks have fallen up to 34 per cent in 2026 as AI disrupted outsourcing model. Analysts remain cautious on FY27 outlook. They prefer TCS, Infosys, HCLTech, Coforge
Axis MF advises bond investors to gradually add Duration as RBI may avoid aggressive rate hikes despite oil risks and inflation concerns
LTM's acquisition of Randstad's Europe and Australia technology services business expands scale and opens new verticals, but brokerages question whether the deal strengthens AI capabilities
LIC share price rose nearly 5% after Q4FY26 results beat estimates. Strong VNB margins and product mix prompted brokerages to raise targets
Ola Electric Q4FY26 results showed margin gains but brokerages remain cautious on volume recovery, market share and cash conservation
BPCL shares gained after Q4FY26 results, but brokerages remain cautious due to crude prices, LPG under-recoveries and weaker FY27 earnings outlook
Jubilant FoodWorks share price dropped after Q4FY26 results as commodity inflation and weak dine-in demand weighed on margins
Hindalco share price rose nearly 4 per cent today after Novelis posted stronger Q4FY26 results and guided an earlier-than-expected Oswego restart.
GE Vernova shares jumped 9% after strong Q4FY26 results. Brokerages raised targets on record ₹21,500-crore backlog, exports and HVDC pipeline
One of major positives for Vodafone Idea, recently, has been the government's reassessment of AGR liabilities, which reduced Vodafone Idea's AGR dues to ₹64,000 crore from ₹87,700 crore
Uno Minda shares fell nearly 6 per cent after the company withheld FY27 growth guidance amid geopolitical uncertainty. Emkay downgraded the stock, citing slower growth and margin pressure
Tata Steel shares fell 5 per cent on Monday, after Q4FY26 results, but analysts remain bullish on strong margins, India demand, Europe recovery, and FY27 growth outlook
FPIs have reduced shareholding in large-cap stocks like HDFC Bank, Reliance and Infosys since 2022 while increasing exposure to Paytm, Eternal, Polycab and healthcare stocks, ICICI Securities said
Delhivery shares slipped nearly 6% despite reporting strong Q4FY26 earnings with sharp margin expansion and robust parcel growth. Analysts continue to remain bullish with targets up to ₹600
Rupee fall in 2026: Emkay Global warns India may need rate hikes by RBI, tighter remittance rules and other policy measures to defend the rupee if crude oil prices remain above $100 per barrel
Analysts have shared a positive outlook on TVS Motor after it reportedstrong Q4FY26 results. EV growth, premiumisation, export strength and rising market share remain key growth drivers, they said
PNB Gilts shares surged nearly 20% after reports suggested India may reduce taxes on bond investments by foreign investors to attract capital and support the rupee
In the March quarter (Q4FY26), Kaynes Technology reported a 21.5 per cent decline in net profit to ₹91.2 crore, as compared to ₹116.2 crore Y-o-Y
Tata Motors CV may trade off profitability for volumes amid rising raw material costs. For now, the company has refrained from giving FY27 growth guidance
Analysts have turned cautious on Dr Reddy's Laboratories after Q4 results raised concerns over weakening US business, sharp Revlimid decline, pricing pressure and delays in semaglutide launches